News
-
2026.05.18ReleaseCUORIPS Inc. Announces Acceptance of Abstract on Groundbreaking Cardiac Regenerative Therapy at AHA's BCVS 2026
-
2026.03.16ReleaseNew Insights into Cardiac Regeneration: hiPSC-derived Cardiomyocytes Patches Remodel the Injured Heart
-
2026.03.06ReleaseWorld’s First iPSC-Derived Cardiomyocyte Therapy for Heart Failure Receives Conditional Approval in Japan
-
2025.06.23ReleaseWe are pleased to announce our participation in Japan Health, to be held from Wednesday, June 25 to Friday, June 27, 2025.
-
2025.04.08ReleaseAnnouncement of Application for Approval of Manufacturing and Marketing of Human (Allogeneic) iPS Cell-derived Cardiomyocyte Patches
-
2024.12.23ReleaseAnnouncement of Joint Research Agreement with Stanford University’s Department of Cardiothoracic Surgery(December 23, 2024 update)
-
2024.12.17ReleaseAnnouncement of Joint Research Agreement with Stanford University's Department of Cardiothoracic Surgery
-
2023.11.15ReleaseAnnouncement of Presentation at AHA (American Heart Association) Scientific Session
-
2023.11.14ReleaseCuorips awarded to occupy at METI's new business center in Silicon Vallery
-
2023.06.27ReleaseCuorips listed on the Tokyo Stock Exchange Growth Market
-
2022.08.29ReleaseAn article in which our CTO Yoshiki Sawa commented was published in the website of "nature" .
-
2022.04.13ReleaseAnnouncement of Joint Research Agreement Regarding New Therapeutic Approach against Cardiovascular Diseases